PL404315A1 - Lek i kompozycja farmaceutyczna zawierajaca 5-hydroksy-7-chloro-1[2-metylo-4(2-metylobenzoiloamino)benzoilo]-2,3,4,5-tetrahydro-1H-benzoazepine do leczenia ciezkiej niewydolnosci serca oraz zastosowanie tego zwiazku do wytwarzania leku - Google Patents

Lek i kompozycja farmaceutyczna zawierajaca 5-hydroksy-7-chloro-1[2-metylo-4(2-metylobenzoiloamino)benzoilo]-2,3,4,5-tetrahydro-1H-benzoazepine do leczenia ciezkiej niewydolnosci serca oraz zastosowanie tego zwiazku do wytwarzania leku

Info

Publication number
PL404315A1
PL404315A1 PL404315A PL40431504A PL404315A1 PL 404315 A1 PL404315 A1 PL 404315A1 PL 404315 A PL404315 A PL 404315A PL 40431504 A PL40431504 A PL 40431504A PL 404315 A1 PL404315 A1 PL 404315A1
Authority
PL
Poland
Prior art keywords
drug
heart failure
methylbenzoylamino
tetrahydro
benzoyl
Prior art date
Application number
PL404315A
Other languages
English (en)
Inventor
Atsushi Ozaki
Yosuke Maki
Osamu Sato
Yoshitaka Yamamuro
Original Assignee
Otsuka Pharmaceutical Co.,Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32908667&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL404315(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharmaceutical Co.,Ltd. filed Critical Otsuka Pharmaceutical Co.,Ltd.
Publication of PL404315A1 publication Critical patent/PL404315A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Przedmiotem wynalazku jest lek oraz kompozycja farmaceutyczna do leczenia ciezkiej niewydolnosci serca klasy IV wedlug Nowojorskiego Towarzystwa Kardiologicznego, w przypadku której pacjenci sa niezdolni do podjecia jakiejkolwiek aktywnosci fizycznej bez odczuwania dolegliwosci, objawy niewydolnosci serca lub dusznicy bolesnej sa obecne nawet w spoczynku, a podjecie jakiejkolwiek aktywnosci fizycznej nasila dolegliwosci, przy czym lek oraz kompozycja zawieraja jako skladnik czynny 5-hydroksy-7-chloro-1-[2-metylo-4-(2-metylobenzoiloamino) benzoilo]-2,3,4,5-tetrahydro-1H-benzoazepine lub jej farmaceutycznie dopuszczalna sól. Przedmiotem wynalazku jest równiez zastosowanie 5-hydroksy-7-chloro-1-[2-metylo-4-(2-metylobenzoiloamino) benzoilo]-2,3,4,5-tetrahydro-1H-benzoazepiny lub jej farmaceutycznie dopuszczalnej soli do wytwarzania leku odpowiedniego do leczenia ciezkiej niewydolnosci serca klasy IV wedlug Nowojorskiego Towarzystwa Kardiologicznego.
PL404315A 2003-02-24 2004-02-23 Lek i kompozycja farmaceutyczna zawierajaca 5-hydroksy-7-chloro-1[2-metylo-4(2-metylobenzoiloamino)benzoilo]-2,3,4,5-tetrahydro-1H-benzoazepine do leczenia ciezkiej niewydolnosci serca oraz zastosowanie tego zwiazku do wytwarzania leku PL404315A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44887803P 2003-02-24 2003-02-24

Publications (1)

Publication Number Publication Date
PL404315A1 true PL404315A1 (pl) 2013-08-05

Family

ID=32908667

Family Applications (2)

Application Number Title Priority Date Filing Date
PL404315A PL404315A1 (pl) 2003-02-24 2004-02-23 Lek i kompozycja farmaceutyczna zawierajaca 5-hydroksy-7-chloro-1[2-metylo-4(2-metylobenzoiloamino)benzoilo]-2,3,4,5-tetrahydro-1H-benzoazepine do leczenia ciezkiej niewydolnosci serca oraz zastosowanie tego zwiazku do wytwarzania leku
PL373432A PL218069B1 (pl) 2003-02-24 2004-02-23 Lek i kompozycja farmaceutyczna do zastosowania w leczeniu ciężkiej niewydolności serca oraz zastosowanie 5-hydroksy-7-chloro-1-[ 2-metylo-4-( 2-metylobenzoiloamino) benzoilo]-2,3,4,5-tetrahydro-1H-benzoazepiny do wytwarzania leku do leczenia ciężkiej niewydolności serca

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL373432A PL218069B1 (pl) 2003-02-24 2004-02-23 Lek i kompozycja farmaceutyczna do zastosowania w leczeniu ciężkiej niewydolności serca oraz zastosowanie 5-hydroksy-7-chloro-1-[ 2-metylo-4-( 2-metylobenzoiloamino) benzoilo]-2,3,4,5-tetrahydro-1H-benzoazepiny do wytwarzania leku do leczenia ciężkiej niewydolności serca

Country Status (24)

Country Link
US (2) US7423032B2 (pl)
EP (2) EP2000142A1 (pl)
JP (2) JP4771937B2 (pl)
KR (1) KR100706727B1 (pl)
CN (1) CN100577171C (pl)
AR (1) AR043259A1 (pl)
AT (1) ATE411803T1 (pl)
AU (2) AU2004212842B9 (pl)
BR (1) BRPI0405657A (pl)
CA (1) CA2493475A1 (pl)
CY (1) CY1108583T1 (pl)
DE (1) DE602004017283D1 (pl)
DK (1) DK1596868T3 (pl)
ES (1) ES2315640T3 (pl)
HK (1) HK1084037A1 (pl)
MX (1) MXPA05001623A (pl)
MY (1) MY143740A (pl)
NO (1) NO335369B1 (pl)
PL (2) PL404315A1 (pl)
PT (1) PT1596868E (pl)
RU (2) RU2346689C2 (pl)
SI (1) SI1596868T1 (pl)
TW (1) TWI322689B (pl)
WO (1) WO2004073716A1 (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7468390B2 (en) * 2002-01-17 2008-12-23 Novartis Ag Methods of treatment and pharmaceutical composition
TWI322689B (en) * 2003-02-24 2010-04-01 Otsuka Pharma Co Ltd Method for treating severe heart failure and medicament therefor
DE102005003632A1 (de) 2005-01-20 2006-08-17 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Katheter für die transvaskuläre Implantation von Herzklappenprothesen
US20070213813A1 (en) 2005-12-22 2007-09-13 Symetis Sa Stent-valves for valve replacement and associated methods and systems for surgery
BRPI0620715A2 (pt) 2005-12-27 2011-11-22 Otsuka Pharma Co Ltd composto da benzoazepina solúvel em água e a sua composição farmacêutica
JP5076327B2 (ja) * 2006-02-01 2012-11-21 味の素株式会社 分岐鎖アミノ酸の心不全適応
US7896915B2 (en) 2007-04-13 2011-03-01 Jenavalve Technology, Inc. Medical device for treating a heart valve insufficiency
ES2421639T3 (es) * 2007-05-15 2013-09-04 Otsuka Pharma Co Ltd Métodos para utilizar antagonistas de vasopresina con agentes quimioterapéuticos de antraciclina para reducir la cardiotoxicidad y/o mejorar la supervivencia
TWI405574B (zh) * 2007-06-21 2013-08-21 Otsuka Pharma Co Ltd 藥學固體製劑及其製造方法
ES2903231T3 (es) 2008-02-26 2022-03-31 Jenavalve Tech Inc Stent para el posicionamiento y anclaje de una prótesis valvular en un sitio de implantación en el corazón de un paciente
US9044318B2 (en) 2008-02-26 2015-06-02 Jenavalve Technology Gmbh Stent for the positioning and anchoring of a valvular prosthesis
JP2013526388A (ja) 2010-05-25 2013-06-24 イエナバルブ テクノロジー インク 人工心臓弁、及び人工心臓弁とステントを備える経カテーテル搬送体内プロテーゼ
JP5477413B2 (ja) * 2012-04-24 2014-04-23 味の素株式会社 分岐鎖アミノ酸の心不全適応
JP6563394B2 (ja) 2013-08-30 2019-08-21 イェーナヴァルヴ テクノロジー インコーポレイテッド 人工弁のための径方向に折り畳み自在のフレーム及び当該フレームを製造するための方法
CN107530168B (zh) 2015-05-01 2020-06-09 耶拿阀门科技股份有限公司 在心脏瓣膜替换中具有降低的起搏器比例的装置和方法
EP3454795B1 (en) 2016-05-13 2023-01-11 JenaValve Technology, Inc. Heart valve prosthesis delivery system for delivery of heart valve prosthesis with introducer sheath and loading system
JP7094965B2 (ja) 2017-01-27 2022-07-04 イエナバルブ テクノロジー インク 心臓弁模倣
CN110174474B (zh) * 2019-05-24 2022-02-18 石家庄四药有限公司 复方电解质注射液(ⅱ)中l-苹果酸异构体的检测方法
CN112121051B (zh) * 2020-09-30 2021-06-18 郑州大学 莫扎伐坦在制备抗消化道肿瘤药物中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5258510A (en) 1989-10-20 1993-11-02 Otsuka Pharma Co Ltd Benzoheterocyclic compounds
EP0450097B1 (en) 1989-10-20 1996-04-24 Otsuka Pharmaceutical Co., Ltd. Benzoheterocyclic compounds
US5753677A (en) 1989-10-20 1998-05-19 Otsuka Pharmaceutical Co., Ltd. Benzoheterocyclic compounds
WO1994001113A1 (en) 1992-07-02 1994-01-20 Otsuka Pharmaceutical Company, Limited Oxytocin antagonist
JPH0680641A (ja) 1992-09-01 1994-03-22 Otsuka Pharmaceut Co Ltd 光学活性な５−ヒドロキシベンゾアゼピン誘導体の製造法
TW354762B (en) 1993-02-23 1999-03-21 Otsuka Pharma Co Ltd Agent for prophylaxis or treatment of cataract
JP2694319B2 (ja) 1993-12-24 1997-12-24 大塚製薬株式会社 抗潰瘍剤
JP3002766B2 (ja) * 1994-12-09 2000-01-24 大塚製薬株式会社 脳浮腫治療剤
JPH10120592A (ja) 1996-10-22 1998-05-12 Otsuka Pharmaceut Co Ltd メニエール病乃至メニエール症候群治療剤
JP4210355B2 (ja) 1997-07-03 2009-01-14 大塚製薬株式会社 固形製剤組成物
WO2001054677A2 (en) 2000-01-26 2001-08-02 Warner-Lambert Company Ace inhibitor-vasopressin antagonist combinations
US20030103983A1 (en) * 2002-05-09 2003-06-05 Pressler Milton Lethan Ace inhibitor-vasopressin antagonist combinations
US20030008860A1 (en) 2002-05-09 2003-01-09 Bakker-Arkema Rebecca Guggemos Treatment of congestive heart failure
CA2357833C (en) * 2000-10-04 2005-11-15 Warner-Lambert Company Treatment of pulmonary hypertension using vasopressin antagonist
TWI322689B (en) * 2003-02-24 2010-04-01 Otsuka Pharma Co Ltd Method for treating severe heart failure and medicament therefor

Also Published As

Publication number Publication date
RU2346689C2 (ru) 2009-02-20
TW200418489A (en) 2004-10-01
CY1108583T1 (el) 2014-04-09
WO2004073716A1 (en) 2004-09-02
RU2005102110A (ru) 2005-09-20
RU2008133654A (ru) 2010-02-20
NO335369B1 (no) 2014-12-01
PL218069B1 (pl) 2014-10-31
TWI322689B (en) 2010-04-01
JP4771937B2 (ja) 2011-09-14
CN100577171C (zh) 2010-01-06
AR043259A1 (es) 2005-07-20
US7423032B2 (en) 2008-09-09
AU2009201109A1 (en) 2009-04-09
AU2004212842B9 (en) 2009-03-05
PT1596868E (pt) 2009-01-14
NO20050569D0 (no) 2005-02-02
EP1596868B1 (en) 2008-10-22
US20080214523A1 (en) 2008-09-04
US7749993B2 (en) 2010-07-06
US20050187210A1 (en) 2005-08-25
CN1700919A (zh) 2005-11-23
JP2011148806A (ja) 2011-08-04
JP2006518731A (ja) 2006-08-17
CA2493475A1 (en) 2004-09-02
MY143740A (en) 2011-07-15
EP1596868A1 (en) 2005-11-23
KR20050105972A (ko) 2005-11-08
MXPA05001623A (es) 2005-04-25
KR100706727B1 (ko) 2007-04-12
AU2004212842B2 (en) 2009-01-08
PL373432A1 (pl) 2005-08-22
AU2004212842A1 (en) 2004-09-02
BRPI0405657A (pt) 2005-07-19
SI1596868T1 (sl) 2008-12-31
ES2315640T3 (es) 2009-04-01
DE602004017283D1 (de) 2008-12-04
EP2000142A1 (en) 2008-12-10
NO20050569L (no) 2005-11-22
DK1596868T3 (da) 2008-12-08
HK1084037A1 (en) 2006-07-21
ATE411803T1 (de) 2008-11-15
EP1596868A4 (en) 2006-03-29

Similar Documents

Publication Publication Date Title
PL404315A1 (pl) Lek i kompozycja farmaceutyczna zawierajaca 5-hydroksy-7-chloro-1[2-metylo-4(2-metylobenzoiloamino)benzoilo]-2,3,4,5-tetrahydro-1H-benzoazepine do leczenia ciezkiej niewydolnosci serca oraz zastosowanie tego zwiazku do wytwarzania leku
Madhusoodanan et al. Clinical experience with quetiapine in elderly patients with psychotic disorders
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
EA200800056A1 (ru) Каннабиноидный активный фармацевтический ингредиент для лекарственных форм
HK1088547A1 (en) Once daily dosage forms of trospium trospium
WO2002088100A3 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
BR9915610A (pt) Preparações farmacêuticas combinadas
HUP0301390A2 (hu) Valzartánt tartalmazó orális gyógyászati készítmény
RU2008110933A (ru) Применение амброксола для лечения риновирусных инфекций
CA2450915A1 (en) Use of levosimendan and beta-adrenergic receptor antagonist for the treatment of heart failure
MA28036A1 (fr) Utilisation d'oxcarbazepine dans le traitement de la douleur liee a la neuropathie diabetique et dans l'amelioration du sommeil
JP2002535367A5 (pl)
MXPA02006511A (es) Complejo que comprende factor inhibidor de osteoclastogenesis y polisacarido.
CA2501772A1 (en) Use of dihydroimidazolones for the treatment of epilepsy in dogs
CA2474430A1 (en) A combination of a thrombolytic agent and levosimendan for the treatment of acute myocardial infarction
HUP0301408A2 (hu) Szulodexid alkalmazása diabetikus vesebetegség kezelésére szolgáló orális gyógyszerkészítmény előállítására
AU2012276476B2 (en) Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation
AR030551A1 (es) Uso de nefiracetam para la fabricacion de un medicamento para eltratamiento de la neurodegeneracion y composicion farmaceutica resultante
CZ2004719A3 (cs) Léčivo s obsahem darifenacinu pro ošetřování nucení na močení souvisejícího s hyperaktivním měchýřem
Kamalakkannan et al. Chronotherapy of Cardiac Diseases using Diltiazem HCl-A Review
PT1490049E (pt) Citalopram para o tratamento da pre3ssao sanguinia elevada.
TW200515912A (en) Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep
HUP0401587A2 (hu) Új elnyújtott kibocsátású orális adagolási forma
Hemmeter et al. P. 6.023 Effect of zopiclone on cognition and sleep-EEG in healthy elderly volunteers
RS51331B (en) USE OF PIPAMPERON AND D2-RECEPTOR ANTAGONISTS OR SEROTONIN / DOPAMINE ANTAGONISTS FOR THE TREATMENT OF PSYCHOTIC DISORDERS